Stock HRTX HERON THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Heron Therapeutics, Inc.

Equities

HRTX

US4277461020

Real-time Estimate Cboe BZX
Other stock markets
 14:44:19 29/04/2024 BST 		5-day change 1st Jan Change
2.515 USD +2.65% Intraday chart for Heron Therapeutics, Inc. -7.20% +44.12%
04-23 Capital One Starts Heron Therapeutics With Overweight Rating, $6 Price Target MT
03-21 Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Heron Therapeutics, Inc. Announces Executive Changes, Effective March 29, 2024
Sector Update: Health Care Stocks Slipping Late Afternoon
Heron Therapeutics Shares Soar After Q4 Results Beat
Heron Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Heron Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024
Heron Therapeutics Says FDA Approved Expanded Label for Zynrelef to Add More Orthopedic, Soft Tissue Procedures
Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures
Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Monday Amid Boeing 737 Max 9 Grounding
Heron Therapeutics Unveils Deal to Expand Sales Network for Postoperative Pain Control Anesthetic; Shares Rise Premarket
Heron Therapeutics, Inc. Enters into Five-Year Distributor Partnership with Crosslink Life Sciences, LLC to Expand the Sales Network Supporting ZYNRELEF
Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023
Heron Therapeutics Insider Bought Shares Worth $137,970, According to a Recent SEC Filing
Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024
Heron Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023
Heron Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Insider Buy: Heron Therapeutics
Heron Therapeutics Cuts Workforce by 25%
Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HRTX Stock
  4. News Heron Therapeutics, Inc.
  5. Other languages